June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Function of a soluble VEGF receptor 2 protein in vivo
Author Affiliations & Notes
  • Xinyuan Zhang
    Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Wei Liu
    Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Ching Song
    University of Science and Technology Beijing, Beijing, China
  • Ningli Wang
    Beijing TongRen Hospital, Beijing, China
    Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Footnotes
    Commercial Relationships Xinyuan Zhang, None; Wei Liu, None; Ching Song, None; Ningli Wang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 61. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xinyuan Zhang, Wei Liu, Ching Song, Ningli Wang; Function of a soluble VEGF receptor 2 protein in vivo. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):61.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To test the function of a truncated, soluble vascular endothelial growth factor receptor 2 (sVEGFR2) possessing the combined-functional domains 1-3 and 5 in vivo.

Methods: The inhibitory function of the sVEGFR2 was test in vivo. A rat Vegfr2 gene restriction fragment encoding a truncated sVEGFR2 protein, which contains the immunoglobulin-like domains 1-3 and 5, was cloned into the eukaryotic expression vector pCMV6 via recombinant DNA technology. The resulting pCMV6-sVegfr2 plasmid was transfected in human embryonic kidney (HEK) 293 cells via liposomal transient transfection. ELISA was used to quantify VEGFA, VEGFR2 and sVEGFR2 protein in the conditioned medium. . Full-length rat VEGFR2 encoded by the pCMV6-rVegfr2 plasmid was used as a control.

Results: Soluble VEGFR2 produced by pCMV6-truncated-rVegfr2 inhibited full-length VEGFR2 protein expression in the cell membrane. The amount of full-length VEGFR2 protein in the pCMV6-truncated-rVegfr2 transfected cells was 20% lower than that in the negative control (non-transfected HEK 293 cells). Expression of VEGFA was significantly decreased in the pCMV6-truncated-rVegfr2 trasfected cells conpared with the negtive control cells ( 25.5± 2.1% vs. 52.2± 1.8 P=0.000). Either pCMV6-truncated-rat-Vegfr2 (pCMV6-truncated-rVegfr2) or pCMV6-rVegfr2 inhibited the expression of intracellular green fluorescent protein. The sVEGFR2 protein content was found to increase by approximately 26% in the transfected cells compared to that in the negative control cells (68.2% ± 1.7% vs. 41.9% ± 2.9%, P = 0.000) and by 18% compared to the negative control cells (68.2% ± 1.7% vs. 50.0% ± 0.5%, P = 0.003). Propidium iodide and Hoechst staining indicated no significant change in the number of HEK293 cells undergoing apoptosis 6 days after pCMV6-trucated-Vegfr2 transfection, compared to the negative control.

Conclusions: Recombinant sVEGFR2 inhibited the expression of endogenous full-length VEGFR2 and VEGFA but was not cytotoxic.This study employed a eukaryotic system to express sVEGFR2 while maintaining its natural configuration and normal function by preserving the glycosylation and disulfide bonds in the extracellular VEGFR2 fragment.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.